Kancera prepares for clinical development

2016-09-21

Kancera AB (publ) announced today that Niclas Brynne has been appointed to lead Kancera’s clinical development projects. He will be part of the management team and report directly to the CEO.

Niclas Brynne (born 1961) holds a Ph.D. in Medical Sciences, Clinical Pharmacology. He has more than 25 years of experience from clinical development positions at Pharmacia and AstraZeneca. In these companies, Niclas has been responsible for progressing new discoveries from preclinical research through clinical development to marketed drugs. Most recently Niclas comes from a position as Senior VP, Head Clinical Projects, at Mentiscura Diagnostics.

"Kancera has developed a portfolio of preclinical drug projects against cancer diseases that cannot be cured with existing therapies. The next step in Kancera’s development is to test selected candidate drugs in humans. We are therefore pleased to welcome Niclas Brynne, who provides a broad knowledge and extensive experience of clinical development of new treatment concepts”, says Thomas Olin, CEO of Kancera AB.

About Kancera AB
Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera is currently developing drugs for the treatment of leukemia and solid tumors, based on blocking survival signals in the cancer cell and on addressing cancer metabolism. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 15 people. Kancera shares are traded on NASDAQ First North and the number of shareholders with more than 500 shares were 7700 as of July, 2016. FNCA is Kancera’s Certified Adviser. Professor Carl-Henrik Heldin, Professor Håkan Mellstedt, and MD PhD Charlotte Edenius are board members and Kancera´s scientific advisers.

For further information, please contact,
Thomas Olin, CEO: +46 (0) 735 20 40 01
Address:
Kancera AB (publ)
Karolinska Institutet Science Park,
Banvaktsvägen 22
SE 171 48 Solna

Please visit the company website; http://www.kancera.com 


Recieve our releases/reports by email when they are distributed.
Press releases
Interim reports
Yearly reports


Subscribe
Unsubscribe

Copyright 2010 KANCERA AB, KAROLINSKA INSTITUTET SCIENCE PARK, BANVAKTSVÄGEN 22, 171 48 SOLNA. TEL: +46 (0)850 12 60 80 Website policy